🔗 Share this article

Former Prime Minister Rishi Sunak has intensified his appeal for a specialized screening programme for prostate gland cancer.

In a recently conducted interview, he expressed being "persuaded of the critical importance" of introducing such a system that would be cost-effective, deliverable and "save numerous lives".

These statements emerge as the National Screening Advisory Body reviews its determination from five years ago against recommending standard examination.

News sources suggest the authority may maintain its current stance.

Athlete Adds Support to Campaign

Gold medal cyclist Sir Chris Hoy, who has advanced prostate cancer, wants younger men to be checked.

He suggests lowering the age threshold for requesting a prostate-specific antigen blood test.

Currently, it is not routinely offered to men without symptoms who are below fifty.

The PSA examination is controversial however. Measurements can rise for causes apart from cancer, such as bacterial issues, resulting in false positives.

Opponents contend this can cause unwarranted procedures and complications.

Focused Testing Initiative

The recommended examination system would concentrate on males between 45 and 69 with a hereditary background of prostate cancer and African-Caribbean males, who experience double the risk.

This group encompasses around over a million men in the United Kingdom.

Research projections indicate the initiative would require £25 million annually - or about eighteen pounds per patient - akin to colorectal and mammary cancer screening.

The assumption includes twenty percent of suitable candidates would be notified yearly, with a nearly three-quarters uptake rate.

Diagnostic activity (imaging and tissue samples) would need to increase by almost a quarter, with only a reasonable increase in medical workforce, based on the study.

Clinical Community Response

Some healthcare professionals are uncertain about the value of examination.

They argue there is still a risk that individuals will be treated for the disease when it is not absolutely required and will then have to endure complications such as urinary problems and impotence.

One leading urology professional commented that "The challenge is we can often identify conditions that might not necessitate to be treated and we potentially create harm...and my apprehension at the moment is that harm to benefit ratio isn't quite right."

Patient Experiences

Personal stories are also influencing the debate.

A particular example features a sixty-six year old who, after requesting a PSA test, was detected with the cancer at the time of 59 and was advised it had metastasized to his hip region.

He has since experienced chemotherapy, radiation treatment and hormone treatment but remains incurable.

The patient supports testing for those who are at higher risk.

"That is very important to me because of my boys – they are in their late thirties and early forties – I want them screened as quickly. If I had been tested at fifty I am confident I might not be in the position I am currently," he stated.

Next Steps

The National Screening Committee will have to weigh up the data and viewpoints.

While the recent study suggests the consequences for personnel and availability of a testing initiative would be achievable, others have contended that it would take diagnostic capabilities away from individuals being cared for for other conditions.

The ongoing debate highlights the complicated balance between timely diagnosis and likely overtreatment in prostate gland cancer care.